ArticleNPJ digital medicine2026
An EEG-based digital biomarker for personalizing transcranial magnetic stimulation in major depressive disorder.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Transcranial magnetic stimulation (TMS) is a promising treatment for Major Depressive Disorder (MDD), but its effectiveness varies significantly across individuals, necessitating biomarkers for pretreatment stratification. We developed an EEG-based digital biomarker, the dorsolateral prefrontal cortex (dlPFC) sensitivity index (dSI), to predict response to repetitive TMS. In Study 1, dSI was computed from EEG functional connectivity features using an L1-regularized logistic regression model. In Study 2, patients were prospectively stratified into sensitive, non-sensitive, and sham groups, all undergoing a personalized, neuronavigated bilateral dlPFC rTMS protocol for two weeks. Baseline EEG-derived dlPFC sensitivity index (dSI) significantly predicted clinical and cognitive outcomes following rTMS. Patients prospectively identified as 'sensitive' based on their pretreatment dSI exhibited greater improvements in emotional attention network task reaction times and more pronounced reductions in hostility and paranoia compared to 'non-sensitive' and sham groups. Post-TMS EEG analysis further confirmed network-specific modulation in the sensitive group. These findings support the predictive validity of this EEG-based task biomarker for personalizing TMS treatment in MDD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.